Saturday 17 October 2026
Export ALNY’s income statement to Excel — free account
Alnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue grew 66.9%, EPS grew 341.2%, free cash flow grew 152.8% and total debt fell 1.51%, each against the same quarter a year earlier. Member of the Nasdaq 100; revenue growth for five consecutive years.
231.83
2.20
−0.94%
Follow ALNY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
51.30 | 80.14 | 163.12 | 748.40 |
+8 more quarters Free account |
P/S ratio |
8.37 | 10.26 | 14.03 | 18.67 | |
P/FCF ratio |
49.06 | 68.35 | 111.94 | 270.78 | |
P/Operating CF |
123.10 | 623.66 | 318.51 | 170.75 | |
P/B ratio |
29.70 | 40.89 | 66.01 | 256.27 | |
Price to Tangible BV |
29.70 | 40.89 | 66.01 | 256.27 | |
EV/Sales |
7.89 | 9.79 | 13.51 | 18.15 | |
EV/EBITDA |
35.96 | 52.01 | 90.08 | 181.47 | |
EV/Operating CF |
41.59 | 58.71 | 95.77 | 219.12 | |
EV/FCF |
46.25 | 65.24 | 107.85 | 263.17 | |
Quick Ratio |
2.79 | 2.89 | 2.51 | 2.37 | |
Current Ratio |
3.05 | 3.13 | 2.76 | 2.54 | |
Net Debt/EBITDA |
(9.36) | (7.09) | (13.09) | (4.41) | |
Debt/Assets |
18.19% | 19.68% | 20.29% | 21.44% | |
Debt/Equity |
0.75 | 0.94 | 1.28 | 4.45 | |
Asset Turnover |
0.95 | 0.92 | 0.81 | 0.71 | |
Operating CF/Net income |
1.99 | 0.34 | 1.07 | 1.40 | |
Capex/Depreciation |
(2.50) | (1.61) | (1.72) | (0.88) | |
Interest Coverage |
2.82 | 3.88 | 1.49 | 8.29 | |
Research and Development Expense of Revenue |
32.00% | 31.26% | 33.93% | 28.73% | |
Selling, General and Administrative Expense of Revenue |
26.95% | 27.64% | 29.66% | 25.79% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
6.71% | 6.01% | 6.53% | 8.66% | |
Graham Net Nets |
0.01 | 0.00 | 0.00 | (0.01) | |
Graham Number |
36.58 | 27.42 | 18.18 | 4.94 | |
Earnings Yield |
1.95% | 1.25% | 0.61% | 0.13% | |
Free Cash Flow Yield |
2.04% | 1.46% | 0.89% | 0.37% | |
Revenue per Share |
9.66 | 8.78 | 8.37 | 9.50 | |
Operating CF per Share |
2.45 | 0.53 | 1.25 | 2.67 | |
Capex per Share |
(0.26) | (0.16) | (0.18) | (0.09) | |
Free Cash Flow per Share |
2.19 | 0.37 | 1.07 | 2.58 | |
Cash per Share |
24.76 | 22.64 | 22.20 | 20.73 | |
Shareholders Equity per Share |
10.14 | 8.09 | 6.02 | 1.78 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.14 | 8.09 | 6.02 | 1.78 | |
Free Cash Flow |
292.04 | 48.67 | 140.26 | 338.89 | |
Working Capital |
3,107.66 | 2,869.83 | 2,584.31 | 2,397.33 | |
Capital Expenditures |
(34.68) | (21.83) | (23.29) | (12.14) | |
Net Current Asset Value |
415.52 | 165.14 | (126.49) | (664.96) | |
EV/EBIT |
37.93 | 55.80 | 100.07 | 220.08 | |
Capex to Sales |
0.03 | 0.02 | 0.02 | 0.01 | |
Price to Operating Income |
40.23 | 58.46 | 103.86 | 226.44 | |
| Other line items | |||||
Average Receivables |
739.93 | 651.00 | 591.44 | 659.31 | |
Average Payables |
105.20 | 112.01 | 102.07 | 94.20 | |
Average Inventory |
84.40 | 74.80 | 80.61 | 75.69 | |
Average Assets |
5,062.39 | 4,671.68 | 4,603.16 | 4,528.35 | |
Average Common Equity |
802.35 | 595.41 | 428.13 | 133.12 |
Columns are period end dates